Komori
Mitsubishi Chemical Group (4188) · TargetSoftened

APTSIS 20 target for a high-growth, high-profitability corporate group

First written in FY2016. 4 of 10 entries say "Restated". Latest entry: FY2021.

10entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2017-Q3RestatedFY2018-Q1RaisedFY2018 – FY2019-Q3RestatedFY2019SoftenedFY2020 – FY20212016: 220162017: 320172018: 120182019: 220192020: 120202021: 12021
Same theme, other companies
Setting and achieving performance targets under the medium-term management planA theme 889 companies write about · 88 as a headwind · 1169 as a tailwind

The whole theme swung hardest in 2021: 19 of 83 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 135 companies compared. The sentences above are computed from all 135.Comparing 200 of the theme's 1305 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2021SoftenedAnnual report

    「Core operating profit reached ¥380 billion in fiscal 2017, but declined from fiscal 2018 onward due to the non-recognition of revenue from part of the royalty income from Gilenya in accordance with IFRS 15, following the commencement of arbitration proceedings in February 2019, as well as the impact of the US-China trade conflict and the COVID-19 pandemic.」

    The fiscal 2020 targets under APTSIS20 were core operating profit of ¥174.7 billion, ROS of 5.4%, a loss attributable to owners of the parent of ¥7.6 billion, ROE of -0.6% and a net debt-to-equity ratio of 1.73, all substantially below target. The shortfall against the final-year target is explicitly presented as an actual result.
  2. FY2020SoftenedAnnual report

    「We are targeting core operating profit of ¥410 billion in the final year of APTSIS 20.」

    While maintaining the final-year target of ¥410 billion, the main text and progress update explicitly state that, in light of the deterioration in financial metrics resulting from the US-China trade conflict, the COVID-19 pandemic and the acquisition of Tanabe Mitsubishi Pharma as a wholly owned subsidiary, “achieving the fiscal 2020 target will also be difficult.”
  3. FY2019RestatedAnnual report

    「“As the plan figures for the final year of APTSIS 20, we set fiscal 2020 targets of core operating income of ¥410 billion, ROS of 9%, profit for the year attributable to owners of the parent of ¥220 billion, ROE of 13% and a net D/E ratio of 1.0.”」

    The company continues to state the fiscal 2020 targets revised in the previous filing.
  4. FY2019-Q3RaisedAnnual report

    「Based on progress under the plan through fiscal 2018, the company decided to revise the financial indicator targets for fiscal 2020, the final year, taking into account growth centered on the performance products segment through acceleration of the above measures, further realization of integration synergies, downside risks from market conditions in the Chemicals segment, and M&A and other activities in the Industrial Gases segment. Details of the revision Financial indicator Fiscal 2020 target (Initial target) Fiscal 2020 target (Revised) Core operating income ¥380 billion ¥410 billion ROS (core operating income margin on revenue) 8% 9% Profit for the year attributable to owners of the parent ¥180 billion ¥220 billion ROE (profit for the year attributable to owners of the parent divided by equity attributable to owners of the parent) 12% 13% Net D/E ratio (debt-to-equity ratio) (Note) 0.8 1.0」

    For the fiscal 2020 targets under APTSIS 20, core operating income, ROS, profit for the year attributable to owners of the parent and ROE were raised to ¥410 billion, 9%, ¥220 billion and 13%, respectively. Meanwhile, the net D/E ratio was revised from 0.8 to 1.0, so the financial targets moved in different directions by indicator.
  5. FY2018RaisedAnnual report

    「In fiscal 2018, we will continue to pursue further transformation and growth, with a view to core operating income of ¥430 billion in the final year of “APTSIS 20.”」

    In addition to the formal fiscal 2020 plan figure of ¥380 billion, the company has added wording indicating that it is targeting a higher level, with ¥430 billion in view for the final year.
  6. FY2018-Q1RestatedAnnual report

    「To achieve the five-year medium-term management plan “APTSIS 20,” covering the five years from April 2016, we integrated our three chemical operating companies, Mitsubishi Chemical Corporation, Mitsubishi Plastics, Inc. and Mitsubishi Rayon Co., Ltd., which were consolidated subsidiaries, effective 1 April 2017, in order to establish a structure capable of responding rapidly to changes in the management environment and making maximum use of management resources.」

    The integration of 3 chemical companies is positioned as an initiative toward achieving APTSIS 20, and the basic policy of the medium-term plan remains unchanged.
  7. FY2017RaisedAnnual report

    「“APTSIS 20” final-year plan figures Financial indicators Fiscal 2020 Core operating income ¥380 billion ROS (core operating income margin on revenue) 8% Profit attributable to owners of the parent ¥180 billion ROE (return on equity attributable to owners of the parent) 12% Net D/E ratio (debt-to-equity ratio) 0.8」

    The company restates the fiscal 2020 targets for APTSIS 20, with ROE raised from the previous target of at least 10% to 12%.
  8. FY2017-Q3RestatedAnnual report

    「Under the medium-term management plan “APTSIS 20,” our Group has adopted the fundamental policy of aiming to become a high-growth, high-profit corporate group through businesses in the performance products, materials and healthcare fields. Using core operating income, ROS, profit attributable to owners of the parent, ROE and the net D/E ratio as financial indicators, we will maintain an appropriate balance among investment in growth businesses, enhanced shareholder returns and strengthening our financial position, thereby working to enhance corporate value.」

    The company continues to state the basic policy and financial indicators of APTSIS 20 and the balance among growth investment, shareholder returns and strengthening its financial position.
  9. FY2017-Q1RestatedAnnual report

    「Under the medium-term management plan “APTSIS 20,” our Group has adopted the fundamental policy of aiming to become a high-growth, high-profit corporate group through businesses in the performance products, materials and healthcare fields. Using core operating income, ROS, profit attributable to owners of the parent, ROE and the net D/E ratio as financial indicators, we will maintain an appropriate balance among investment in growth businesses, enhanced shareholder returns and strengthening our financial position, thereby working to enhance corporate value.」

    The company restates the basic policy and financial indicators of APTSIS 20 and the balance among growth investment, shareholder returns and strengthening its financial position, but does not present new numerical targets.
  10. FY2016First statedAnnual report

    「“Under the basic policy of aiming to become a high-growth, high-profitability corporate group through businesses in the performance products, materials and healthcare fields, we established the following numerical targets for fiscal 2020 as financial indicators.”」

    For fiscal 2020, the company set targets of core operating income of ¥380 billion, ROS of 8%, profit for the year attributable to owners of the parent of ¥180 billion, ROE of at least 10% and a net D/E ratio of 0.8.
Moved together

"Strategic investments, including capital expenditure and M&A, in growth businesses" moved the same way as this thread, in the same document, in 3 of its 10 moves.

322222★123456
  1. ★This thread
  2. 1Strategic investments, including capital expenditure and M&A, in growth businesses3×
  3. 2Portfolio and Structural Reform of the Petrochemicals Business2×
  4. 3Building an Australia and Oceania platform through the acquisition of an industrial-gases business2×
  5. 4Earnings volatility arising from demand, market conditions, raw material prices, foreign exchange and supply constraints2×
  6. 5Funding risks from interest-bearing debt, interest rates and credit-rating downgrades2×
  7. 6Deteriorating profitability and impairment at petrochemical and materials facilities2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Mitsubishi Chemical Group yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.